TOOLS AND RESOURCES

HEAR FROM EXPERTS ABOUT THE DAMAGE THAT MAY BE CAUSED BY LARGELY UNADDRESSED INFLAMMATION AND FIBROSIS IN PATIENTS WITH CKD AND T2D1-6

The Silent Nature of CKD in T2D

The Silent Nature of CKD in T2D

Increased Cardiovascular Risk in Patients with CKD and T2D

Increased Cardiovascular Risk in Patients with CKD and T2D

Early Detection & Intervention in CKD and T2D

Early Detection & Intervention in CKD and T2D

The Need for a Collaborative Multidisciplinary Approach
 in CKD in T2D

The Need for a Collaborative Multidisciplinary Approach
 in CKD in T2D

Patient Education in CKD in T2D

Patient Education in CKD in T2D

The Role of Healthcare Providers Beyond the Specialists

The Role of Healthcare Providers Beyond the Specialists

Inflammation and fibrosis in CKD and T2D as driven by MR overactivation video

Rajiv Agarwal, MD, takes us through how MR overactivation impacts inflammation and fibrosis and leads to CKD progression

The burden of CKD in patients with T2D video

Peter Rossing, MD, discusses the burden that CKD presents for patients with T2D

Living with CKD and T2D: burden and day-to-day management video

Peter Rossing, MD, helps us understand the daily management needs of those living with CKD and T2D

The mode of disease of CKD in patients with T2D video

This video explains the mode of disease behind CKD in patients with T2D

Living with CKD and T2D patient testimonial video

Hear from patients around the world about their experiences living with CKD and T2D

Learn how UACR testing can reveal early kidney damage and act as a predictor of CKD progression7-9
Find out here

CKD: chronic kidney disease; MR: mineralocorticoid receptor; T2D: type 2 diabetes; UACR: urine albumin-to-creatinine ratio.

References:

  • Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313. Return to content
  • Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
  • Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
  • Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
  • Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content
  • ACR. National Kidney Foundation. Accessed January 12, 2021. https://www.kidney.org/kidneydisease/siemens_hcp_acr. Return to content
  • Campion CG, et al. Can J Kidney Health Dis. 2017;4. doi:10.1177/2054358117705371. Return to content
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150. Return to content

Follow:

© 2022 Bayer AG

Last updated in June 2022

This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.

  • PP-KER-ALL-0067-1
Alt tag Alt tag